Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, July 10, 2023

Quanterix launches blood test to detect early Alzheimer’s disease

With your risk of dementia post stroke, how is your doctor objectively determining if you have it? NOTHING LIKE USUAL?  Then you don't have a functioning stroke doctor.

RUN AWAY!

Your risk of dementia, has your doctor told you of this?  Your doctor is responsible for preventing this!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

Quanterix launches blood test to detect early Alzheimer’s disease

Quanterix Corporation announced the launch of LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with signs of early Alzheimer’s disease.

According to a release from Quanterix, the LucentAD test — which is expected to become available to health care providers for use in conjunction with other diagnostic tools — will provide clinicians with a simplified assessment process to determine whether a patient presents with amyloid pathology consistent with AD.

Photo of blood test tubes
A Massachusetts-based biotech firm announced the release of a blood test which will provide clinicians a rapid means to detect early signs of Alzheimer’s disease. Image: Adobe Stock

The LucentAD test measures the protein p-Tau 18 and its concentration in both plasma and cerebrospinal fluid, whose presence correlates to amyloid pathology in the brain. LucentAD uses the Simoa p-Tau 181 assay, whose high analytical sensitivity allows for detection of p-Tau 181, which is a low-abundance protein in blood.

“A year ago, Quanterix announced the validation of our laboratory developed test to quantitatively measure p-Tau 181 in plasma as an aid in diagnostic evaluation of Alzheimer’s disease,” Masoud Toloue, CEO at Quanterix, stated in the release. “The launch of Lucent Diagnostics and availability of the LucentAD test expands access to our p-Tau 181 test for health care providers and marks an important step in our goal to help build a global Alzheimer’s disease testing infrastructure.”

No comments:

Post a Comment